Hedge Fund Wins Subpoena Fight With Merck

Aug 29 2014 | 7:23am ET

Pharmaceutical giant Merck & Co. will have to answer a hedge fund’s questions, a federal judge ruled this week.

U.S. Magistrate Judge Douglas Arpert in Trenton, N.J., ordered Merck to respond to a subpoena issued by BVF Partners, part of its lawsuit against Celera Corp. Celera has a royalty interest in an osteoporosis drug sold by Merck, Odanacatib.

BVF, which runs the Biotechnology Value Fund, has sued Celera for allegedly undervaluing the company as part of its sale to Quest Diagnostics in 2011. In particular, the hedge fund says that Celera downplayed Odanacatib’s value.

Arpert noted that Merck’s “analyses and valuations of Odanacatib could serve as important data points to establish the true value of the drug.”

Odanacatib is still awaiting federal approval.


In Depth

Debunking Conventional Investment Wisdom

Feb 8 2017 | 3:22pm ET

Due diligence in the hedge fund world has long involved some combination of the...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

The Future of Private Equity: New Opportunities, New Challenges

Feb 3 2017 | 6:41pm ET

The private equity industry’s astonishing rebound since the financial crisis has...

 

From the current issue of